Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Da Riva, Luca ^a   Bozzi, Fabio ^a   Mondellini, Piera ^a   Miccichè, Francesca ^a   Fumagalli, Elena ^a   Vaghi, Elena ^a   Tarantino, Eva ^a   Huber, Veronica ^a   Gronchi, Alessandro ^a   Tamborini, Elena ^a   Pierotti, Marco A ^a   Pilotti, Silvana ^a   Bongarzone, Italia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; IMATINIB; STEM CELL FACTOR RECEPTOR; STEM CELL GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; CLEC11A PROTEIN, HUMAN; LECTIN; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FUNCTIONAL PROTEOMICS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; METABOLISM; METHODOLOGY; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS; STROMA CELL; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LECTINS, C-TYPE; PIPERAZINES; PROTEOMICS; PYRIMIDINES; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STROMAL CELLS;

EID: 80053173887     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-158     Document Type: Article

References (41)

1. Gundacker NC, Haudek VJ, Wimmer H, Slany A, Griss J, Bochkov V, et al. Cytoplasmic Proteome and Secretome Profiles of Differently Stimulated Human Dendritic Cells. Journal of Proteome Research 2009, 8:2799-2811. 10.1021/pr8011039, 19351150.
2. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58. 10.1097/00000658-200001000-00008, 1420965, 10636102.
3. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002, 3:655-664. 10.1016/S1470-2045(02)00899-9, 12424067.
4. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005, 103:821-829. 10.1002/cncr.20862, 15648083.
5. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT) - Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology 1998, 152:1259-1269. 1858579, 9588894.
6. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22:3813-3825. 10.1200/JCO.2004.05.140, 15365079.
7. Williams DE, Eisenman J, Baird A, Rauch C, Vanness K, March CJ, et al. Identification of A Ligand for the C-Kit Protooncogene. Cell 1990, 63:167-174. 10.1016/0092-8674(90)90297-R, 1698553.
8. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987, 6:3341-3351. 553789, 2448137.
9. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium. Cell 1990, 63:195-201. 10.1016/0092-8674(90)90300-4, 2208278.
10. Theou-Anton N, Tabone S, Brouty-Boye D, Saffroy R, Ronnstrand L, Lemoine A, et al. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 2006, 94:1180-1185. 10.1038/sj.bjc.6603063, 2361250, 16570044.
11. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005, 13:205-220. 10.1097/01.pai.0000173054.83414.22, 16082245.
12. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour (vol 369, pg 1731, 2007). Lancet 2007, 370:388.
13. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134. 10.1016/S0140-6736(04)17098-0, 15451219.
14. van GM, Verweij J, Casali PG, Le CA, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005, 23:5795-5804. 10.1200/JCO.2005.11.601, 16110036.
15. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 2003, 186:665-669. 10.1016/j.amjsurg.2003.08.023, 14672776.
16. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008, 13:4-7.
17. Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, et al. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clinical Cancer Research 2007, 13:2369-2377. 10.1158/1078-0432.CCR-06-1745, 17438095.
18. Agaram NP, Besmer P, Wong GC, Guo TH, Socci ND, Maki RG, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clinical Cancer Research 2007, 13:170-181. 10.1158/1078-0432.CCR-06-1508, 17200352.
19. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23:3999-4006. 10.1038/sj.onc.1207525, 15007386.
20. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007, 26:7560-7568. 10.1038/sj.onc.1210558, 17546049.
21. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16:910-919. 10.1245/s10434-008-0177-7, 18953611.
22. Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, et al. Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?. Transl Oncol 2008, 1:177-186. 2582166, 19043528.
23. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721. 2732363, 11099404.
24. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010, 21:v98-v102. 10.1093/annonc/mdq208, 20555113.
25. Gorla L, Mondellini P, Cuccuru G, Micciche F, Cassinelli G, Cremona M, et al. Proteomics Study of Medullary Thyroid Carcinomas Expressing RET Germ-Line Mutations: Identification of New Signaling Elements. Molecular Carcinogenesis 2009, 48:220-231. 10.1002/mc.20474, 18756447.
26. Michel PE, Crettaz D, Morier P, Heller M, Gallot D, Tissot JD, et al. Proteome analysis of human plasma and amniotic fluid by Off-Gel (TM) isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 2006, 27:1169-1181. 10.1002/elps.200500680, 16470776.
27. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, et al. 9p21 Locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 2005, 104:159-169. 10.1002/cncr.21113, 15929122.
28. Mercalli E, Ghizzoni S, Arighi E, Alberti L, Sangregorio R, Radice MT, et al. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein. Oncogene 2001, 20:3475-3485. 10.1038/sj.onc.1204462, 11429694.
29. Hiraoka A, Sugimura A, Seki T, Nagasawa T, Ohta N, Shimonishi M, et al. Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:7577-7582. 10.1073/pnas.94.14.7577, 23864, 9207134.
30. Kojouharova M, Reid K, Gadjeva M. New insights into the molecular mechanisms of classical complement activation. Molecular Immunology 2010, 47:2154-2160. 10.1016/j.molimm.2010.05.011, 20542571.
31. Ito C, Sato H, Ando K, Watanabe S, Yoshiba F, Kishi K, et al. Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation. Bone Marrow Transplantation 2003, 32:391-398. 10.1038/sj.bmt.1704152, 12900775.
32. Hiraoka A, Yano KK, Kagami N, Takeshige K, Mio H, Anazawa H, et al. Stem cell growth factor: in situ hybridization analysis on the gene expression, molecular characterization and in vitro proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cells. Hematol J 2001, 2:307-315. 10.1038/sj.thj.6200118, 11920266.
33. Mio H, Kagami N, Yokokawa S, Kawai H, Nakagawa S, Takeuchi K, et al. Isolation and characterization of a cDNA for human, mouse, and rat full-length stem cell growth factor, a new member of C-type lectin superfamily. Biochemical and Biophysical Research Communications 1998, 249:124-130. 10.1006/bbrc.1998.9073, 9705843.
34. Perrin C, Bayle J, Bannwarth S, Michiels JF, Heudier P, Lefebvre JC, et al. Expression of LSLCL, a new C-type lectin, is closely restricted, in bone marrow, to immature neutrophils. C R Acad Sci III 2001, 324:1125-1132. 10.1016/S0764-4469(01)01392-0, 11803813.
35. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004, 101:6062-6067. 10.1073/pnas.0400782101, 395923, 15075390.
36. Hiraoka A. Leukemia cell lines require self-secreted stem cell growth factor (SCGF) for their proliferation. Leukemia Research 2008, 32:1623-1625. 10.1016/j.leukres.2008.01.003, 18289675.
37. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3:e3077. 10.1371/journal.pone.0003077, 2518121, 18728788.
38. Bhojwani D, Kang HN, Moskowitz NP, Min DJ, Lee H, Potter JW, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006, 108:711-717. 10.1182/blood-2006-02-002824, 1895482, 16822902.
39. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
40. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Annals of Medicine 2001, 33:451-455. 10.3109/07853890109002093, 11680792.
41. Sontheimer RD, Racila E, Racila DM. C1q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. J Invest Dermatol 2005, 125:14-23. 10.1111/j.0022-202X.2005.23673.x, 15982298.